GHK-Cu has the stronger published research footprint because it is a specific peptide-copper complex
Frequently referenced in the National Library of Medicine, research indicates this specific compound demonstrates a unique capability to stimulate endogenous growth hormone pathways without significantly elevating cortisol or prolactin levels
It acts on a different appetite-regulating hormone pathway from Wegovy, Zepbound, Ozempic, Mounjaro, and Foundayo, which all involve GLP-1
Avoid using the medication if you have a history of medullary thyroid carcinoma, pancreatitis, severe gastrointestinal disorders, or multiple endocrine neoplasia type 2 (MEN2) syndrome
We just dont know what that timeline looks like. She went on to say that during the period when this is all hashed out, other medications will likely be introduced that could upend everythingagain